OS Fund

en.wikipedia.org/wiki/OS_Fund

VCMatch tracks OS Fund as an investor focused on AI/ML, Biotech, and Pharma companies, Seed and Series A rounds, and United States markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Seed, Series A

Focus Areas

AI/ML, Biotech, Pharma

Geography

United States

Investment Thesis

OS Fund’s investment philosophy is to back early-stage, science-first platform companies that conventional VCs avoid — filling a perceived gap from a “pullback in federal support of research and development” and a “general reluctance by more traditional venture capital firms to make science-related investments.” The firm targets foundational, platform-level technologies (the fund’s name draws on the “operating system” metaphor) and prefers computationally driven approaches — using AI/ML to accelerate discovery — with the aim of enabling large, systemic change across genomics, synthetic biology, therapeutics, materials and diagnostics.

Is OS Fund right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

OS Fund is most relevant for founders raising Seed and Series A rounds in AI/ML, Biotech, Pharma, and Medtech, especially across United States.

Focus statement

OS Fund "invests in early-stage science and technology companies" and "focuses on early-stage, computationally driven companies that utilize artificial intelligence and machine learning to develop platform technologies in genomics, synthetic biology, computationally derived therapeutics, advanced materials, and diagnostics."

Value Add

Explicit science-first mandate aimed at areas "more traditional venture capital firms" are reluctant to back (response to reduced federal R&D support).
Focus on platform-level, foundational technologies across genomics, synthetic biology, advanced materials, diagnostics and computational therapeutics (stated list of sectors).
Preference for computationally driven companies that "utilize artificial intelligence and machine learning" to build platform technologies.
Transparency and evangelism for the field: OS Fund "published the methodology it uses to evaluate investments" in synthetic biology and publicly released the "playbook" to encourage others to invest in emerging sciences.
Founder-backed, mission-oriented capital (Bryan Johnson "devoted $100 million from the sale to establishing the fund"), allowing a willingness to take on science & long-horizon risk.